SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, is pleased to announce the...
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, today announced its upcoming oral presentations...
ShapeTX announces the expansion of its drug discovery partnership with Roche with new target
Japanese pharmaceutical company Otsuka has enlisted Seattle-based RNA editing biotech Shape Therapeutics to develop new adeno-associated virus (AAV) vectors. The hope is to find new ways to deliver gene therapies to treat eye diseases.
SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced the appointment of Adrian W. Briggs, Ph.D. as Chief...
SEATTLE, May 04, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced seven presentations from across its technology...
SEATTLE, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ShapeTX today announced Francois Vigneault, Ph.D., Co-founder and Chief Executive Officer, will present at the J.P. Morgan 41st Annual Healthcare...
ProQR Therapeutics is deepening its ties with Eli Lilly, agreeing on Thursday to expand a deal the two struck in 2021 to use the Dutch biotechnology company’s technology to edit RNA.
SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), the RNA technology company advancing programmable medicine, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Shape Therapeutics® Inc. the RNA technology company advancing programmable medicine, today announced new data from its RNAfix®, RNAskipTM and AAVidTM...